DANTRIUM (dantrolene sodium) by Pfizer is clinical pharmacology: in isolated nerve-muscle preparation, dantrium has been shown to produce relaxation by affecting the contractile response of the muscle at a site beyond the myoneural junction. Approved for malignant hyperthermia. First approved in 1979.
Drug data last refreshed 20h ago · AI intelligence enriched 2w ago
DANTRIUM (dantrolene sodium) is an injectable skeletal muscle relaxant that dissociates excitation-contraction coupling by interfering with calcium release from the sarcoplasmic reticulum. It is indicated for malignant hyperthermia crisis management and prophylaxis, and has been used off-label for heat stroke. The drug works directly on muscle tissue beyond the neuromuscular junction to reduce myoplasmic calcium and reverse hypermetabolic cascade.
Product approaching loss of exclusivity with minimal Part D spending signals declining team investment and consolidation toward generic transition.
CLINICAL PHARMACOLOGY: In isolated nerve-muscle preparation, Dantrium has been shown to produce relaxation by affecting the contractile response of the muscle at a site beyond the myoneural junction. In skeletal muscle, Dantrium dissociates the excitation-contraction coupling, probably by…
Worked on DANTRIUM at Pfizer? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moPfizer is hiring 1 role related to this product
DANTRIUM offers limited career trajectory given LOE status, minimal linked job postings, and commoditized competitive landscape dominated by RYANODEX. Positions on this asset typically involve defensive generic transition management and surgical/OR channel relationships rather than growth-oriented brand building.